A study to test whether BI 1819479 improves lung function in people with idiopathic pulmonary fibrosis (IPF).

Prior treatment

• Treated with immunosuppressive medications (other than oral corticosteroids) or prednisone >15 mg/day or equivalent for respiratory or pulmonary reasons.

Other illness

• Patients with a significant disease or condition other than the IPF under study, which in the opinion of the investigator, may put the patient at risk because of participation, interfere with trial procedures, or cause concern regarding the patient’s ability to participate in the trial or any medical condition which could lead to a life expectancy <12 months.
• Lower respiratory tract infection requiring treatment within 4 weeks and/or during the screening period

Other

• Acute IPF exacerbation within at least 12 weeks and/or during the screening period
• Relevant airways obstruction (pre-bronchodilator FEV1/FVC <0.7).
• In the opinion of the Investigator, other clinically significant pulmonary abnormalities.
• Further exclusion criteria apply.

• Patients ≥40 years old at the time of signed informed consent.
• Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
• Diagnosis of IPF based on 2022 ATS/ERS/JRS/ALAT Guidelines
• On stable treatment with nintedanib or pirfenidone for at least 12 weeks or not on treatment with either nintedanib or pirfenidone for at least 12 weeks
• Forced Vital Capacity (FVC) ≥45% of predicted normal.
• DLCO ≥25% of predicted normal corrected for hemoglobin (Hb).
• Women of childbearing potential (WOCBP) must use highly effective methods of birth control with low user dependency and additional barrier contraception for male partners (use of condom) until end of follow-up period.
• Male trial participants with WOCBP partners must use contraception (condom) to avoid exposure via seminal fluid. Female partners of male trial participants must use highly effective methods of contraception during treatment until end of follow-up period.